MX2020008454A - Composicion inmunogenica que comprende antigenos estafilococicos. - Google Patents

Composicion inmunogenica que comprende antigenos estafilococicos.

Info

Publication number
MX2020008454A
MX2020008454A MX2020008454A MX2020008454A MX2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
staphylococcal antigens
staphylococcal
antigens
conjugates
Prior art date
Application number
MX2020008454A
Other languages
English (en)
Inventor
Fabio Bagnoli
Carine Goraj
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020008454A publication Critical patent/MX2020008454A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona una composición inmunogénica que comprende antígenos estafilocócicos, que contiene antígenos proteicos y conjugados de polisacáridos capsulares, en particular Hla, ClfA, SpA y conjugados de polisacáridos capsulares. También se proporcionan formulaciones adyuvantes. La invención puede encontrar uso en la prevención y el tratamiento de infecciones estafilocócicas, en particular infección y enfermedad por S. aureus.
MX2020008454A 2018-02-13 2019-02-12 Composicion inmunogenica que comprende antigenos estafilococicos. MX2020008454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens

Publications (1)

Publication Number Publication Date
MX2020008454A true MX2020008454A (es) 2021-03-25

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008454A MX2020008454A (es) 2018-02-13 2019-02-12 Composicion inmunogenica que comprende antigenos estafilococicos.

Country Status (15)

Country Link
US (2) US11426455B2 (es)
EP (1) EP3752183A1 (es)
JP (1) JP2021514387A (es)
KR (1) KR20200121825A (es)
CN (1) CN112153980A (es)
AR (1) AR114627A1 (es)
AU (1) AU2019221496B2 (es)
BR (1) BR112020016373A2 (es)
CA (1) CA3090609A1 (es)
EA (1) EA202091690A1 (es)
GB (1) GB201802339D0 (es)
IL (1) IL276661B2 (es)
MX (1) MX2020008454A (es)
SG (1) SG11202007676RA (es)
WO (1) WO2019158537A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
WO2021219047A1 (zh) * 2020-05-01 2021-11-04 神州细胞工程有限公司 一种增强蛋白/肽抗原免疫原性的方法
JP7423133B2 (ja) 2020-09-21 2024-01-29 エルジー エナジー ソリューション リミテッド リチウム二次電池の活性化方法及びリチウム二次電池

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101505496B1 (ko) * 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
CN101983067B (zh) * 2008-01-31 2017-07-11 近都柏林之伊丽莎白皇后神圣及不可分割的三位一体学院之教务长,研究员和学者 微生物感染的治疗
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
BRPI1015567A2 (pt) * 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
SG186290A1 (en) * 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
AU2011346535B2 (en) 2010-12-22 2015-09-24 Wyeth Llc Stable immunogenic compositions of Staphylococcus aureus antigens
EP2744517B1 (en) * 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
JP2016540764A (ja) 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
EP3639850A1 (en) 2014-03-26 2020-04-22 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Also Published As

Publication number Publication date
AU2019221496B2 (en) 2022-12-08
US11426455B2 (en) 2022-08-30
KR20200121825A (ko) 2020-10-26
SG11202007676RA (en) 2020-09-29
GB201802339D0 (en) 2018-03-28
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
US20210023192A1 (en) 2021-01-28
CN112153980A (zh) 2020-12-29
WO2019158537A1 (en) 2019-08-22
US20230052495A1 (en) 2023-02-16
BR112020016373A2 (pt) 2020-12-15
EP3752183A1 (en) 2020-12-23
AR114627A1 (es) 2020-09-30
CA3090609A1 (en) 2019-08-22
JP2021514387A (ja) 2021-06-10
EA202091690A1 (ru) 2020-11-27
IL276661B2 (en) 2023-08-01
AU2019221496A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
MX2023014569A (es) Anticuerpos anti-sirpa.
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
PH12018500037A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2019005423A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs).
MA45283B1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
MX2017016858A (es) Composiciones inmunogenicas.
MX2022001937A (es) Composicion inmunogenica.
EP4361262A3 (en) Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
PH12020550059A1 (en) Novel ophthalmic composition and methods of use
PL412612A1 (pl) Szczep Gram-dodatniej laseczki Bacillus subtillis, rekombinowane przetrwalniki, kompozycja immunogenna, doustna szczepionka oraz jej zastosowanie przeciwko wirusowi grypy typu A